March 2024—Agilent Technologies announced an agreement with Incyte to develop companion diagnostics in hematology and oncology. The agreement enables Agilent to continue to expand its companion diagnostics portfolio with novel biomarkers and Incyte to leverage Agilent’s expertise in IVD assay development, global regulatory approvals, and commercialization to support clinical trials as well as the potential registration and commercialization of companion diagnostics in the United States and Europe.
Newsbytes
April 2023—At the medical center of the University of Medicine and Pharmacy at Ho Chi Minh City, patients are not screened for bladder cancer using urine cytology because the pathology department does not have the capability for such screening. But that may soon change, thanks to an organization focused on using digital pathology to increase the availability of pathology education resources in developing countries.
Read More »Agilent releases on-deck thermal cycler for Bravo NGS platform
March 2023—Agilent Technologies released an on-deck thermal cycler that integrates with the company’s Bravo NGS automated liquid handling platform. The optional accessory enables the Bravo platform to provide thermal cycling as part of an automated protocol and extends walkaway time. The setup is beneficial, the company says, for applications such as library preparation and target enrichment steps in next-generation sequencing workflows, end-point PCR, and cell-based applications.
Read More »Agilent announces global distribution agreement with Proscia
March 10, 2023—Agilent Technologies announced a multiyear distribution agreement with Proscia to offer a comprehensive digital diagnostic pathology system, combining Agilent’s pathology staining solutions with Proscia’s Concentriq Dx enterprise pathology platform.
Read More »Agilent, Akoya to develop multiplex IHC solutions
February 2023—Agilent Technologies announced a partnership with Akoya Biosciences to develop chromogenic and immunofluorescent multiplex assays that include spatial analysis for biopharma companies developing precision cancer therapeutics. The agreement aims to deliver an end-to-end multiplex solution integrating Agilent’s Dako Omnis staining instrument and Akoya’s PhenoImager HT imaging platform.
Read More »Agilent, Quest to extend access to Agilent Resolution ctDx First assay
February 2023—Agilent Technologies announced an agreement with Quest Diagnostics that will enable providers and patients in the United States to access the Agilent Resolution ctDx First liquid biopsy next-generation sequencing test.
Read More »Agilent, Akoya Biosciences to develop multiplex IHC solutions
Jan. 17, 2023—Agilent Technologies announced a partnership with Akoya Biosciences to develop chromogenic and immunofluorescent multiplex assays that include spatial analysis for biopharma companies developing precision cancer therapeutics.
Read More »Agilent CDx expands CE-IVD mark
September 2021—Agilent Technologies announced that its PD-L1 IHC 22C3 pharmDx assay is CE-IVD marked for use as an aid in identifying esophageal cancer patients for treatment with Keytruda using a combined positive score of ≥10.
Read More »Agilent to acquire Resolution Bioscience
March 3, 2021—Agilent Technologies announced it has entered into a definitive agreement to acquire Resolution Bioscience, a next-generation-sequencing–based technology company.
Read More »Agilent releases SureSelect RNA reagent kit
October 2020—Agilent Technologies released the SureSelect XT HS2 RNA reagent kit. The kit enables users to accurately profile gene expression and detect RNA fusions using low-input FFPE samples and aims to significantly improve efficiency, especially in labs that process both DNA and RNA samples for next-generation–sequencing applications.
Read More »Agilent PD-L1 assay FDA approved as CDx
May 19, 2020—Agilent Technologies announced that the Food and Drug Administration has approved the
Read More »Agilent microarrays for pre-, postnatal research
April 2020—Agilent Technologies introduced three microarrays to meet the needs of cytogenetic laboratories conducting prenatal and postnatal research.
Read More »Newsbytes
R programming language gains steam in pathology labs April 2020—Among laboratories focused on expanding data analytics, the statistical programming language R has a loyal user base that is steadily growing. “There is a crew of us that are really trying to show the utility of R for laboratories,” says Stephen Master, MD, PhD, chief of the Division of Laboratory Medicine and director of the Michael Palmieri Laboratory for Metabolic and Advanced Diagnostics at Children’s Hospital of Philadelphia.
Read More »Agilent introduces SureSelect DNA Kit
March 2020—Agilent Technologies introduced the SureSelect XT HS2 DNA Kit, designed to address key challenges that laboratories encounter when preparing DNA sequencing libraries for their research.
Read More »Agilent introduces SureSelect DNA Kit
Feb. 18, 2020—Agilent Technologies introduced the SureSelect XT HS2 DNA Kit, designed to address key challenges that laboratories encounter when preparing DNA sequencing libraries for their research.
Read More »Agilent CDx gets expanded approvals
December 2019—The FDA approved Agilent Technologies’ PD-L1 IHC 22C3 pharmDx assay as an aid in identifying patients with esophageal squamous cell carcinoma for treatment with Keytruda (pembrolizumab), an anti-PD-1 therapy manufactured by Merck. Keytruda is approved for patients with recurrent locally advanced or metastatic ESCC whose tumors express PD-L1 (combined positive score ³10), as determined by an FDA-approved test, with disease progression on or after one prior line of systemic therapy.
Read More »Agilent introduces cell analyzer, flow cytometer
November 2019—Agilent Technologies introduced its xCELLigence RTCA eSight multimode real-time cell analyzer. The research use only system provides label-free, real-time biosensor measurements and kinetic imaging of the same live cell populations independently or simultaneously.
Read More »Agilent introduces library prep system for NGS
May 2019—Agilent Technologies announced its Magnis NGS Prep System, a fully automated next-generation sequencing library preparation system designed to run complex DNA sequencing assays.
Read More »FDA expands pembrolizumab indication for NSCLC
May 2019—The Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for the first-line treatment of patients with stage III non-small cell lung cancer who are not candidates for surgical resection or definitive chemoradiation or metastatic NSCLC.
Read More »FDA expands use of pembrolizumab for NCSLC
May 1, 2019—The Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for the first-line
Read More »Agilent acquires ProZyme, Ultra Scientific
September 2018—Agilent Technologies has entered into a definitive agreement to acquire ProZyme, a provider of glycan analysis reagents, kits, and standards. The acquisition will expand Agilent’s portfolio of biopharma consumables.
Read More »Agilent companion Dx gets expanded approval
August 2018—Agilent Technologies announced that the FDA has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use. PD-L1 IHC 22C3 pharmDx is a laboratory test doctors can use to identify the protein programmed cell death ligand 1 in tumor tissue obtained from patients with lung and gastric cancer.
Read More »FDA expands use of Agilent CDx for gastric cancer , 11/17
November 2017—Agilent Technologies announced its Dako PD-L1 IHC 22C3 pharmDx assay has an expanded label approved by the FDA for use as an aid in identifying gastric or gastroesophageal junction adenocarcinoma patients for treatment with Keytruda (pembrolizumab), an anti-PD-1 therapy manufactured by Merck.
Read More »Newsbytes, 8/16
August 2016—Document-management systems worthwhile if you go extra mile; HHS releases guidance on ransomware attacks; McKesson alters IT business; Leica sample-tracking system added to Psyche products; Agilent buys iLab Solutions
Read More »Newsbytes, 7/15
July 2015—Why Sonora Quest gave itself high marks for LIS conversion; Pathologists share homegrown software for infant autopsies; CMS promotes innovation by offering data to private sector; Agilent purchases Cartagenia; Database provides information from next-gen sequencing
Read More »NGS cancer research panels, 11/14
November 2014—Agilent Technologies introduced ClearSeq AML, a next-generation cancer research panel that targets 48 selected exons in 20 of the most commonly mutated genes found in acute myeloid leukemia.
Read More »SureFISH probes, 3/14
March 2014—Agilent Technologies introduced SureFISH ALK, ROS1, and RET break-apart translocation probes, expanding its offering of oligonucleotide-based fluorescent in situ hybridization products. The probes are repeat-free, able to target specific sequences of interest, and use high-fidelity oligos designed in silico.
Read More »FFPE hybridization buffer, 3/14
March 2014—Agilent Technologies introduced the IQFISH FFPE Hybridization buffer, which enables one-hour hybridization for FISH processing on formalin-fixed paraffin-embedded tissue samples.
Read More »Strand-specific RNA library prep kit, 4/13:86
Agilent Technologies’ SureSelect strand-specific RNA library preparation kit for whole transcriptome and targeted RNA sequencing allows researchers to prepare high-quality, strand-specific libraries for next-generation sequencing. The ability to gain strand-specific information from RNA sequencing experiments allows researchers to more easily discern overlapping transcripts and investigate antisense expression to better understand gene regulation.
Read More »Exome kits, software for next-gen sequencing, 4/13:84
Agilent Technologies’ HaloPlex exome kits and SureCall software complement the company’s Web-based SureDesign interface and custom HaloPlex gene panels to provide a complete, integrated workflow. The HaloPlex exome kit comprises about 2.5 million probes to provide comprehensive coverage of the coding regions of the human genome with minimal hands-on time. The kit requires only 200 ng of input DNA.
Read More »